{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02163694_BROCADE3\\NCT02163694_BROCADE3_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "ITT population",
        "text": "Includes randomized subjects who have been documented to have suspected deleterious or deleterious mutations by the sponsor core lab. In this population subjects will be grouped according to the treatment assigned at randomization.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "ITT",
        "populationDescription": "Includes randomized subjects who have been documented to have suspected deleterious or deleterious mutations by the sponsor core lab. In this population subjects will be grouped according to the treatment assigned at randomization.",
        "criteria": "Randomized AND documented suspected deleterious or deleterious mutations by sponsor core lab"
      },
      {
        "id": "pop_2",
        "name": "As-Treated population",
        "text": "Includes subjects who receive at least one dose of study drug (veliparib or placebo). In this population subjects will be grouped by the actual treatment received on the first dosing day.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "AST",
        "populationDescription": "Includes subjects who receive at least one dose of study drug (veliparib or placebo). In this population subjects will be grouped by the actual treatment received on the first dosing day.",
        "criteria": "Received >= 1 dose of study drug (veliparib or placebo)"
      },
      {
        "id": "pop_3",
        "name": "Crossover population",
        "text": "Includes subjects who receive at least one dose of veliparib in the crossover study period.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Crossover",
        "populationDescription": "Includes subjects who receive at least one dose of veliparib in the crossover study period.",
        "criteria": "Received >= 1 dose of veliparib during the crossover study period"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Continuous demographic data summarized with mean, standard deviation, minimum, maximum, and range."
      },
      {
        "id": "char_2",
        "name": "BRCA Status",
        "code": "BRCA_STATUS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "BRCA Status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Core lab and historical BRCA1 and BRCA2 status."
      },
      {
        "id": "char_3",
        "name": "ER/PgR status",
        "code": "ER/PGR_STATUS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ER/PgR status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Receptor status (ER/PgR+, triple-negative)."
      },
      {
        "id": "char_4",
        "name": "ECOG performance status",
        "code": "ECOG_PERFORMANCE_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ECOG performance status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Eastern Cooperative Oncology Group performance status at baseline."
      },
      {
        "id": "char_5",
        "name": "Prior platinum therapy use",
        "code": "PRIOR_PLATINUM_THERA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior platinum therapy use",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "History of prior platinum therapy (yes versus no)."
      }
    ],
    "summary": {
      "populationCount": 3,
      "characteristicCount": 5
    }
  }
}